세계의 인간 인슐린 시장 규모, 점유율, 동향 분석 : 증상별, 제품 유형별, 인슐린 유형별, 유통 채널별, 지역별 전망 및 예측(2024-2031년)

The Global Human Insulin Market size is expected to reach $20.5 billion by 2031, rising at a market growth of 3.2% CAGR during the forecast period.

Germany, France, and the United Kingdom are among the countries in Europe with a substantial diabetic population. These countries have comprehensive healthcare systems that offer extensive support for diabetes management. The availability of advanced insulin products, including analogs and innovative delivery systems, has driven the European market. Consequently, the European region would acquire nearly 31% of the total market share by 2031.

The expansion of the market is being driven by a number of significant causes, one of the most important of which is the worldwide increase in the population of diabetic patients. The development of type 2 diabetes has been facilitated by the environment created by modern lifestyles, which are characterized by a decrease in physical activity and an increase in the ingestion of unhealthy foods. Hence, the increasing prevalence of diabetes, driven by a combination of genetic, demographic, lifestyle, and environmental factors, is a primary driver of the market.

Additionally, Innovations such as insulin pens, pumps, and continuous glucose monitoring (CGM) systems have revolutionized diabetes management, enhancing patient compliance, convenience, and overall quality of life. Continuous glucose monitoring systems represent a leap forward in diabetes management technology. Thus, the continuous evolution of these technologies is a significant driver of growth in the market.

However, Insulin prices have escalated dramatically over the past several decades, far outpacing inflation and wage growth. Even in developed countries, the high cost of insulin presents a formidable challenge. Although health insurance may cover some of the cost, out-of-pocket expenses can still be prohibitively high. Hence, the high cost of insulin is hampering the market's growth.

Moreover, Economic repercussions of the pandemic strained the market. Many individuals faced financial hardships due to job losses and reduced income, which impacted their ability to afford medications, including insulin. With social distancing measures and restrictions on in-person visits, telemedicine became vital for managing diabetes remotely. Thus, the pandemic had an overall negative impact on the market.

Indication Outlook

On the basis of indication, the market is classified into type 1 diabetes, type 2 diabetes, and gestational diabetes. The type 2 diabetes segment recorded a 40% revenue share in the market in 2023. The prevalence of type 2 diabetes is higher than that of type 1 diabetes, and it is commonly associated with lifestyle variables such as being overweight, deficient in physical activity and having an unhealthy diet.

Product Type Outlook

Based on product type, the market is divided into pens, syringes, and others. The syringes segment procured 30% revenue share in the market in 2023. Affordability is a significant driver, making syringes a viable option for patients in low- and middle-income countries and those without extensive health insurance coverage.

Type of Insulin Outlook

By type of insulin, the market is divided into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and others. The short-acting insulin segment garnered 23% revenue share in the market in 2023. Short-acting insulins, such as regular insulin, have an onset of action within 30 minutes to an hour and peak in about two to four hours.

Distribution Channel Outlook

Based on distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment acquired 37% revenue share in the market in 2023. Drug stores and retail pharmacies are accessible and familiar to many patients, providing a convenient option for obtaining insulin and other diabetes-related supplies.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded 36% revenue share in the market in 2023. The region is home to a significant portion of the global diabetic population, with countries such as the US and Canada experiencing high and rising prevalence rates of diabetes.

List of Key Companies Profiled

• MannKind Corporation
• Lupin Limited
• Sanofi S.A.
• Novo Nordisk A/S
• Eli Lilly And Company
• Medtronic PLC
• Biocon Limited
• Tonghua Dongbao Pharmaceutical Co., Ltd.
• Pfizer, Inc.

Global Human Insulin Market Report Segmentation

By Indication

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

By Product Type

• Pens
• Syringes
• Others

By Type of Insulin

• Rapid-acting insulin
• Short-acting insulin
• Intermediate-acting insulin
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Human Insulin Market, by Indication
  • 1.4.2 Global Human Insulin Market, by Product Type
  • 1.4.3 Global Human Insulin Market, by Type of Insulin
  • 1.4.4 Global Human Insulin Market, by Distribution Channel
  • 1.4.5 Global Human Insulin Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges
• 3.3 Porter Five Forces Analysis

Chapter 4. Global Human Insulin Market by Indication

• 4.1 Global Type 1 Diabetes Market by Region
• 4.2 Global Type 2 Diabetes Market by Region
• 4.3 Global Gestational Diabetes Market by Region

Chapter 5. Global Human Insulin Market by Product Type

• 5.1 Global Pens Market by Region
• 5.2 Global Syringes Market by Region
• 5.3 Global Others Market by Region

Chapter 6. Global Human Insulin Market by Type of Insulin

• 6.1 Global Rapid-acting insulin Market by Region
• 6.2 Global Short-acting insulin Market by Region
• 6.3 Global Intermediate-acting insulin Market by Region
• 6.4 Global Others Market by Region

Chapter 7. Global Human Insulin Market by Distribution Channel

• 7.1 Global Hospital Pharmacies Market by Region
• 7.2 Global Drug Stores & Retail Pharmacies Market by Region
• 7.3 Global Online Providers Market by Region

Chapter 8. Global Human Insulin Market by Region

• 8.1 North America Human Insulin Market
  • 8.1.1 North America Human Insulin Market by Indication
    • 8.1.1.1 North America Type 1 Diabetes Market by Country
    • 8.1.1.2 North America Type 2 Diabetes Market by Country
    • 8.1.1.3 North America Gestational Diabetes Market by Country
  • 8.1.2 North America Human Insulin Market by Product Type
    • 8.1.2.1 North America Pens Market by Country
    • 8.1.2.2 North America Syringes Market by Country
    • 8.1.2.3 North America Others Market by Country
  • 8.1.3 North America Human Insulin Market by Type of Insulin
    • 8.1.3.1 North America Rapid-acting insulin Market by Country
    • 8.1.3.2 North America Short-acting insulin Market by Country
    • 8.1.3.3 North America Intermediate-acting insulin Market by Country
    • 8.1.3.4 North America Others Market by Country
  • 8.1.4 North America Human Insulin Market by Distribution Channel
    • 8.1.4.1 North America Hospital Pharmacies Market by Country
    • 8.1.4.2 North America Drug Stores & Retail Pharmacies Market by Country
    • 8.1.4.3 North America Online Providers Market by Country
  • 8.1.5 North America Human Insulin Market by Country
    • 8.1.5.1 US Human Insulin Market
      • 8.1.5.1.1 US Human Insulin Market by Indication
      • 8.1.5.1.2 US Human Insulin Market by Product Type
      • 8.1.5.1.3 US Human Insulin Market by Type of Insulin
      • 8.1.5.1.4 US Human Insulin Market by Distribution Channel
    • 8.1.5.2 Canada Human Insulin Market
      • 8.1.5.2.1 Canada Human Insulin Market by Indication
      • 8.1.5.2.2 Canada Human Insulin Market by Product Type
      • 8.1.5.2.3 Canada Human Insulin Market by Type of Insulin
      • 8.1.5.2.4 Canada Human Insulin Market by Distribution Channel
    • 8.1.5.3 Mexico Human Insulin Market
      • 8.1.5.3.1 Mexico Human Insulin Market by Indication
      • 8.1.5.3.2 Mexico Human Insulin Market by Product Type
      • 8.1.5.3.3 Mexico Human Insulin Market by Type of Insulin
      • 8.1.5.3.4 Mexico Human Insulin Market by Distribution Channel
    • 8.1.5.4 Rest of North America Human Insulin Market
      • 8.1.5.4.1 Rest of North America Human Insulin Market by Indication
      • 8.1.5.4.2 Rest of North America Human Insulin Market by Product Type
      • 8.1.5.4.3 Rest of North America Human Insulin Market by Type of Insulin
      • 8.1.5.4.4 Rest of North America Human Insulin Market by Distribution Channel
• 8.2 Europe Human Insulin Market
  • 8.2.1 Europe Human Insulin Market by Indication
    • 8.2.1.1 Europe Type 1 Diabetes Market by Country
    • 8.2.1.2 Europe Type 2 Diabetes Market by Country
    • 8.2.1.3 Europe Gestational Diabetes Market by Country
  • 8.2.2 Europe Human Insulin Market by Product Type
    • 8.2.2.1 Europe Pens Market by Country
    • 8.2.2.2 Europe Syringes Market by Country
    • 8.2.2.3 Europe Others Market by Country
  • 8.2.3 Europe Human Insulin Market by Type of Insulin
    • 8.2.3.1 Europe Rapid-acting insulin Market by Country
    • 8.2.3.2 Europe Short-acting insulin Market by Country
    • 8.2.3.3 Europe Intermediate-acting insulin Market by Country
    • 8.2.3.4 Europe Others Market by Country
  • 8.2.4 Europe Human Insulin Market by Distribution Channel
    • 8.2.4.1 Europe Hospital Pharmacies Market by Country
    • 8.2.4.2 Europe Drug Stores & Retail Pharmacies Market by Country
    • 8.2.4.3 Europe Online Providers Market by Country
  • 8.2.5 Europe Human Insulin Market by Country
    • 8.2.5.1 Germany Human Insulin Market
      • 8.2.5.1.1 Germany Human Insulin Market by Indication
      • 8.2.5.1.2 Germany Human Insulin Market by Product Type
      • 8.2.5.1.3 Germany Human Insulin Market by Type of Insulin
      • 8.2.5.1.4 Germany Human Insulin Market by Distribution Channel
    • 8.2.5.2 UK Human Insulin Market
      • 8.2.5.2.1 UK Human Insulin Market by Indication
      • 8.2.5.2.2 UK Human Insulin Market by Product Type
      • 8.2.5.2.3 UK Human Insulin Market by Type of Insulin
      • 8.2.5.2.4 UK Human Insulin Market by Distribution Channel
    • 8.2.5.3 France Human Insulin Market
      • 8.2.5.3.1 France Human Insulin Market by Indication
      • 8.2.5.3.2 France Human Insulin Market by Product Type
      • 8.2.5.3.3 France Human Insulin Market by Type of Insulin
      • 8.2.5.3.4 France Human Insulin Market by Distribution Channel
    • 8.2.5.4 Russia Human Insulin Market
      • 8.2.5.4.1 Russia Human Insulin Market by Indication
      • 8.2.5.4.2 Russia Human Insulin Market by Product Type
      • 8.2.5.4.3 Russia Human Insulin Market by Type of Insulin
      • 8.2.5.4.4 Russia Human Insulin Market by Distribution Channel
    • 8.2.5.5 Spain Human Insulin Market
      • 8.2.5.5.1 Spain Human Insulin Market by Indication
      • 8.2.5.5.2 Spain Human Insulin Market by Product Type
      • 8.2.5.5.3 Spain Human Insulin Market by Type of Insulin
      • 8.2.5.5.4 Spain Human Insulin Market by Distribution Channel
    • 8.2.5.6 Italy Human Insulin Market
      • 8.2.5.6.1 Italy Human Insulin Market by Indication
      • 8.2.5.6.2 Italy Human Insulin Market by Product Type
      • 8.2.5.6.3 Italy Human Insulin Market by Type of Insulin
      • 8.2.5.6.4 Italy Human Insulin Market by Distribution Channel
    • 8.2.5.7 Rest of Europe Human Insulin Market
      • 8.2.5.7.1 Rest of Europe Human Insulin Market by Indication
      • 8.2.5.7.2 Rest of Europe Human Insulin Market by Product Type
      • 8.2.5.7.3 Rest of Europe Human Insulin Market by Type of Insulin
      • 8.2.5.7.4 Rest of Europe Human Insulin Market by Distribution Channel
• 8.3 Asia Pacific Human Insulin Market
  • 8.3.1 Asia Pacific Human Insulin Market by Indication
    • 8.3.1.1 Asia Pacific Type 1 Diabetes Market by Country
    • 8.3.1.2 Asia Pacific Type 2 Diabetes Market by Country
    • 8.3.1.3 Asia Pacific Gestational Diabetes Market by Country
  • 8.3.2 Asia Pacific Human Insulin Market by Product Type
    • 8.3.2.1 Asia Pacific Pens Market by Country
    • 8.3.2.2 Asia Pacific Syringes Market by Country
    • 8.3.2.3 Asia Pacific Others Market by Country
  • 8.3.3 Asia Pacific Human Insulin Market by Type of Insulin
    • 8.3.3.1 Asia Pacific Rapid-acting insulin Market by Country
    • 8.3.3.2 Asia Pacific Short-acting insulin Market by Country
    • 8.3.3.3 Asia Pacific Intermediate-acting insulin Market by Country
    • 8.3.3.4 Asia Pacific Others Market by Country
  • 8.3.4 Asia Pacific Human Insulin Market by Distribution Channel
    • 8.3.4.1 Asia Pacific Hospital Pharmacies Market by Country
    • 8.3.4.2 Asia Pacific Drug Stores & Retail Pharmacies Market by Country
    • 8.3.4.3 Asia Pacific Online Providers Market by Country
  • 8.3.5 Asia Pacific Human Insulin Market by Country
    • 8.3.5.1 China Human Insulin Market
      • 8.3.5.1.1 China Human Insulin Market by Indication
      • 8.3.5.1.2 China Human Insulin Market by Product Type
      • 8.3.5.1.3 China Human Insulin Market by Type of Insulin
      • 8.3.5.1.4 China Human Insulin Market by Distribution Channel
    • 8.3.5.2 Japan Human Insulin Market
      • 8.3.5.2.1 Japan Human Insulin Market by Indication
      • 8.3.5.2.2 Japan Human Insulin Market by Product Type
      • 8.3.5.2.3 Japan Human Insulin Market by Type of Insulin
      • 8.3.5.2.4 Japan Human Insulin Market by Distribution Channel
    • 8.3.5.3 India Human Insulin Market
      • 8.3.5.3.1 India Human Insulin Market by Indication
      • 8.3.5.3.2 India Human Insulin Market by Product Type
      • 8.3.5.3.3 India Human Insulin Market by Type of Insulin
      • 8.3.5.3.4 India Human Insulin Market by Distribution Channel
    • 8.3.5.4 South Korea Human Insulin Market
      • 8.3.5.4.1 South Korea Human Insulin Market by Indication
      • 8.3.5.4.2 South Korea Human Insulin Market by Product Type
      • 8.3.5.4.3 South Korea Human Insulin Market by Type of Insulin
      • 8.3.5.4.4 South Korea Human Insulin Market by Distribution Channel
    • 8.3.5.5 Singapore Human Insulin Market
      • 8.3.5.5.1 Singapore Human Insulin Market by Indication
      • 8.3.5.5.2 Singapore Human Insulin Market by Product Type
      • 8.3.5.5.3 Singapore Human Insulin Market by Type of Insulin
      • 8.3.5.5.4 Singapore Human Insulin Market by Distribution Channel
    • 8.3.5.6 Malaysia Human Insulin Market
      • 8.3.5.6.1 Malaysia Human Insulin Market by Indication
      • 8.3.5.6.2 Malaysia Human Insulin Market by Product Type
      • 8.3.5.6.3 Malaysia Human Insulin Market by Type of Insulin
      • 8.3.5.6.4 Malaysia Human Insulin Market by Distribution Channel
    • 8.3.5.7 Rest of Asia Pacific Human Insulin Market
      • 8.3.5.7.1 Rest of Asia Pacific Human Insulin Market by Indication
      • 8.3.5.7.2 Rest of Asia Pacific Human Insulin Market by Product Type
      • 8.3.5.7.3 Rest of Asia Pacific Human Insulin Market by Type of Insulin
      • 8.3.5.7.4 Rest of Asia Pacific Human Insulin Market by Distribution Channel
• 8.4 LAMEA Human Insulin Market
  • 8.4.1 LAMEA Human Insulin Market by Indication
    • 8.4.1.1 LAMEA Type 1 Diabetes Market by Country
    • 8.4.1.2 LAMEA Type 2 Diabetes Market by Country
    • 8.4.1.3 LAMEA Gestational Diabetes Market by Country
  • 8.4.2 LAMEA Human Insulin Market by Product Type
    • 8.4.2.1 LAMEA Pens Market by Country
    • 8.4.2.2 LAMEA Syringes Market by Country
    • 8.4.2.3 LAMEA Others Market by Country
  • 8.4.3 LAMEA Human Insulin Market by Type of Insulin
    • 8.4.3.1 LAMEA Rapid-acting insulin Market by Country
    • 8.4.3.2 LAMEA Short-acting insulin Market by Country
    • 8.4.3.3 LAMEA Intermediate-acting insulin Market by Country
    • 8.4.3.4 LAMEA Others Market by Country
  • 8.4.4 LAMEA Human Insulin Market by Distribution Channel
    • 8.4.4.1 LAMEA Hospital Pharmacies Market by Country
    • 8.4.4.2 LAMEA Drug Stores & Retail Pharmacies Market by Country
    • 8.4.4.3 LAMEA Online Providers Market by Country
  • 8.4.5 LAMEA Human Insulin Market by Country
    • 8.4.5.1 Brazil Human Insulin Market
      • 8.4.5.1.1 Brazil Human Insulin Market by Indication
      • 8.4.5.1.2 Brazil Human Insulin Market by Product Type
      • 8.4.5.1.3 Brazil Human Insulin Market by Type of Insulin
      • 8.4.5.1.4 Brazil Human Insulin Market by Distribution Channel
    • 8.4.5.2 Argentina Human Insulin Market
      • 8.4.5.2.1 Argentina Human Insulin Market by Indication
      • 8.4.5.2.2 Argentina Human Insulin Market by Product Type
      • 8.4.5.2.3 Argentina Human Insulin Market by Type of Insulin
      • 8.4.5.2.4 Argentina Human Insulin Market by Distribution Channel
    • 8.4.5.3 UAE Human Insulin Market
      • 8.4.5.3.1 UAE Human Insulin Market by Indication
      • 8.4.5.3.2 UAE Human Insulin Market by Product Type
      • 8.4.5.3.3 UAE Human Insulin Market by Type of Insulin
      • 8.4.5.3.4 UAE Human Insulin Market by Distribution Channel
    • 8.4.5.4 Saudi Arabia Human Insulin Market
      • 8.4.5.4.1 Saudi Arabia Human Insulin Market by Indication
      • 8.4.5.4.2 Saudi Arabia Human Insulin Market by Product Type
      • 8.4.5.4.3 Saudi Arabia Human Insulin Market by Type of Insulin
      • 8.4.5.4.4 Saudi Arabia Human Insulin Market by Distribution Channel
    • 8.4.5.5 South Africa Human Insulin Market
      • 8.4.5.5.1 South Africa Human Insulin Market by Indication
      • 8.4.5.5.2 South Africa Human Insulin Market by Product Type
      • 8.4.5.5.3 South Africa Human Insulin Market by Type of Insulin
      • 8.4.5.5.4 South Africa Human Insulin Market by Distribution Channel
    • 8.4.5.6 Nigeria Human Insulin Market
      • 8.4.5.6.1 Nigeria Human Insulin Market by Indication
      • 8.4.5.6.2 Nigeria Human Insulin Market by Product Type
      • 8.4.5.6.3 Nigeria Human Insulin Market by Type of Insulin
      • 8.4.5.6.4 Nigeria Human Insulin Market by Distribution Channel
    • 8.4.5.7 Rest of LAMEA Human Insulin Market
      • 8.4.5.7.1 Rest of LAMEA Human Insulin Market by Indication
      • 8.4.5.7.2 Rest of LAMEA Human Insulin Market by Product Type
      • 8.4.5.7.3 Rest of LAMEA Human Insulin Market by Type of Insulin
      • 8.4.5.7.4 Rest of LAMEA Human Insulin Market by Distribution Channel

Chapter 9. Company Profiles

• 9.1 Biocon Limited
  • 9.1.1 Company Overview
  • 9.1.2 Financial Analysis
  • 9.1.3 Research & Development Expenses
• 9.2 Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 9.2.1 Company Overview
• 9.3 Lupin Limited
  • 9.3.1 Company Overview
  • 9.3.2 Financial Analysis
  • 9.3.3 Regional Analysis
  • 9.3.4 Research & Development Expenses
  • 9.3.5 SWOT Analysis
• 9.4 MannKind Corporation
  • 9.4.1 Company Overview
  • 9.4.2 Financial Analysis
• 9.5 Sanofi S.A.
  • 9.5.1 Company Overview
  • 9.5.2 Financial Analysis
  • 9.5.3 Segmental and Regional Analysis
  • 9.5.4 Research & Development Expense
  • 9.5.5 SWOT Analysis
• 9.6 Novo Nordisk A/S
  • 9.6.1 Company Overview
  • 9.6.2 Financial Analysis
  • 9.6.3 Segmental & Regional Analysis
  • 9.6.4 Research & Development Expenses
  • 9.6.5 SWOT Analysis
• 9.7 Medtronic PLC
  • 9.7.1 Company overview
  • 9.7.2 Financial Analysis
  • 9.7.3 Segmental and Regional Analysis
  • 9.7.4 Research & Development Expenses
  • 9.7.5 SWOT Analysis
• 9.8 Eli Lilly And Company
  • 9.8.1 Company Overview
  • 9.8.2 Financial Analysis
  • 9.8.3 Regional Analysis
  • 9.8.4 Research & Development Expenses
  • 9.8.5 SWOT Analysis
• 9.9 Pfizer, Inc.
  • 9.9.1 Company Overview
  • 9.9.2 Financial Analysis
  • 9.9.3 Regional & Segmental Analysis
  • 9.9.4 Research & Development Expense
  • 9.9.5 SWOT Analysis

Chapter 10. Winning Imperatives for Human Insulin Market